> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # Epitopea Doses First Patient With an Off-the-Shelf mRNA Cancer Vaccine - URL: https://nexi.fund/epitopea-dark-genome-mrna-vaccine/ - Published: 2026-11-12T13:30:00.000Z - Updated: 2026-11-12T13:30:00.000Z - Description: Epitopea's first-in-human OVACT trial has dosed a patient with CryptiVax-1001, an mRNA vaccine built on dark-genome antigens. The milestone confirms execution, not efficacy; the registry points to a 2029 primary completion. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-2, #hook-statistic, #track-E, #layout-sparse-brief On 9 November, a woman with advanced high-grade serous ovarian cancer received an injection no patient had received before. The dose was CryptiVax-1001, Epitopea’s mRNA cancer vaccine, given as maintenance therapy after surgery and first-line platinum chemotherapy. She was the first patient in OVACT, the company’s Phase 1/1b trial. Epitopea says the study will enrol up to 30 women across up to 10 UK sites. The ClinicalTrials.gov record lists an estimated enrolment of 50, which covers the dose-escalation stage plus an optional expansion. Five dose levels are planned, with dose-limiting toxicity checked over the first 21 days. HGSOC is the most common and aggressive subtype of ovarian cancer. Around 80% of patients present with advanced or metastatic disease, and nearly all relapse after first-line platinum chemotherapy. Maintenance options work in about half of the ovarian cancer population, which leaves the HRP-positive, BRCA-wildtype group with little that is matched to their tumour biology. 💡 **OVACT at a glance** Phase 1/1b, open-label, non-randomised. Dose escalation plus optional expansion. Population: FIGO stage III–IV HGSOC, HRP+/BRCA-wildtype, after debulking surgery and first-line platinum. Sites: up to 10 in the UK, from Cambridge and London to Glasgow, Leeds, Leicester and Preston. Estimated primary completion: March 2029\. Registry ID: NCT07665515\. ## What the first dose does not prove A first-in-human dose is an operations milestone. It shows that the protocol, the supply chain and the site network can put a patient on treatment. It does not show that the vaccine works. The primary endpoints are safety and tolerability: treatment-emergent adverse events and dose-limiting toxicities. Immunogenicity is measured. The trial is not powered to demonstrate a survival or remission benefit. The calendar matters more than the announcement. The registry’s estimated primary completion is March 2029\. Any claim that this vaccine extends remission stays a hypothesis until then. Ten UK sites for a dose-escalation study of this size is a lot of geography. That is what a narrow eligibility window looks like in practice: HRP-positive, BRCA-wildtype, stage III–IV disease, no prior cancer vaccine or checkpoint inhibitor, and no recurrence after platinum chemotherapy. The patients who fit are the ones existing maintenance options serve least well. ## Why dark-genome antigens change the manufacturing question CryptiVax-1001 targets antigens that Epitopea’s CryptoMap engine identifies in the so-called dark genome, the non-coding regions long treated as noise. The company calls the resulting targets Cryptigens and says they are shared across patients. That sharing is the commercial point. A shared target set can be manufactured as one product for many patients, instead of a bespoke batch per person. Personalized mRNA cancer vaccines dominate the field’s headlines. Epitopea’s bet is that the off-the-shelf route is the one that scales. We are sceptical of the phrase “off-the-shelf” until the shelf exists at commercial scale. For now it describes a design choice, not a supply chain. As we wrote in November, the next mRNA race is about where the payload acts, not whether mRNA can work ([our look at SRTD’s precision-mRNA seed](https://nexi.fund/srtd-biotech-precision-mrna-seed-2026/)). Epitopea’s version of that argument is antigen selection: find targets that many tumours present, then let the immune system do the matching. The milestone is real. The proof is scheduled for 2029. [ Epitopea announces first patient dosed in the OVACT trial Company release, 9 November 2026: trial design, enrolment target and quotes from the chief medical officer and the chief investigator. Epitopea ](https://www.epitopea.com/epitopea-announces-first-patient-dosed-in-ovact-phase-1-1b-clinical-trial-of-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer/?ref=nexi.fund) The primary announcement. Read the efficacy language as company framing, not as data. [ OVACT: CryptiVax-1001 in high-grade serous ovarian cancer Registry record with phase, endpoints, UK site list, estimated enrolment of 50 and estimated primary completion in March 2029. ClinicalTrials.gov ](https://clinicaltrials.gov/study/NCT07665515?ref=nexi.fund) The best check on the press release: a different enrolment number and a 2029 readout date. [ First patient receives mRNA immunotherapy for ovarian cancer Trade coverage of the dosing milestone, including the patient population and the investigator comment. Drug Discovery World ](https://www.ddw-online.com/first-patient-receives-mrna-immunotherapy-for-ovarian-cancer-44682-202611/?ref=nexi.fund) Independent trade confirmation of the event, useful because it repeats the company’s own trial limits.